J & D Pharmaceuticals Earns Orphan Drug Designation for ADPKD Therapy J & D Pharmaceuticals has received Orphan Drug Designation from the FDA for their investigational therapy JD-004, aimed at treating ADPKD, a rare genetic kidney disorder.

J & D Pharmaceuticals Earns Orphan Drug Designation for ADPKD Therapy #United_States #ADPKD #Orphan_Drug #JD_Pharmaceuticals #Monmouth